Search

Your search keyword '"Marghoob, Ashfaq"' showing total 1,922 results
Start Over Author "Marghoob, Ashfaq"
1,922 results on '"Marghoob, Ashfaq"'

3. Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study

Author

Hawryluk, Elena B., Moustafa, Danna, Barry, Kelly K., Bahrani, Eman, Reusch, Diana B., Brahmbhatt, Meera, Chen, Lily, Coughlin, Carrie C., Gerami, Pedram, Haddock, Ellen, Hook, Kristen, Humphrey, Stephen R., Kao, Pei-Chi, Kruse, Lacey L., Lawley, Leslie P., Mansour, Danny, Marghoob, Ashfaq A., Nguyen, Julie, Phung, Thuy L., Pope, Elena, Raisanen, Tom, Robinson, Sarah, Rogers, Tova, Schmidt, Birgitta, Tran, Gary, Travis, Kate, Wolner, Zachary, London, Wendy B., Eichenfield, Lawrence F., and Huang, Jennifer

Published
2024
Full Text
View/download PDF

4. Expert Agreement on the Presence and Spatial Localization of Melanocytic Features in Dermoscopy

Author

Liopyris, Konstantinos, Navarrete-Dechent, Cristian, Marchetti, Michael A., Rotemberg, Veronica, Apalla, Zoe, Argenziano, Giuseppe, Blum, Andreas, Braun, Ralph P., Carrera, Cristina, Codella, Noel C.F., Combalia, Marc, Dusza, Stephen W., Gutman, David A., Helba, Brian, Hofmann-Wellenhof, Rainer, Jaimes, Natalia, Kittler, Harald, Kose, Kivanc, Lallas, Aimilios, Longo, Caterina, Malvehy, Josep, Menzies, Scott, Nelson, Kelly C., Paoli, John, Puig, Susana, Rabinovitz, Harold S., Rishpon, Ayelet, Russo, Teresa, Scope, Alon, Soyer, H. Peter, Stein, Jennifer A., Stolz, Willhelm, Sgouros, Dimitrios, Stratigos, Alexander J., Swanson, David L., Thomas, Luc, Tschandl, Philipp, Zalaudek, Iris, Weber, Jochen, Halpern, Allan C., and Marghoob, Ashfaq A.

Published
2024
Full Text
View/download PDF

10. Prognostic Gene Expression Profiling in Cutaneous Melanoma

Author

Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K, Marchetti, Michael A, Othus, Megan, Coit, Daniel G, Hartman, Rebecca I, Leachman, Sancy A, Berry, Elizabeth G, Korde, Larissa, Lee, Sandra J, Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I, Burton, Elizabeth M, Chu, Emily Y, Curiel-Lewandrowski, Clara, Curtis, Julia A, Daud, Adil, Deacon, Dekker C, Ferris, Laura K, Gershenwald, Jeffrey E, Grossmann, Kenneth F, Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M, Judson-Torres, Robert L, Kendra, Kari L, Kim, Caroline C, Kirkwood, John M, Lawson, David H, Leming, Philip D, Long, Georgina V, Marghoob, Ashfaq A, Mehnert, Janice M, Ming, Michael E, Nelson, Kelly C, Polsky, David, Scolyer, Richard A, Smith, Eric A, Sondak, Vernon K, Stark, Mitchell S, Stein, Jennifer A, Thompson, John A, Thompson, John F, Venna, Suraj S, Wei, Maria L, and Swetter, Susan M

Subjects
Cancer, Clinical Research, Patient Safety, Prevention, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Clinical Decision-Making, Consensus, Consensus Development Conferences as Topic, Gene Expression Profiling, Humans, Melanoma, Neoplasm Staging, Practice Guidelines as Topic, Prognosis, Sentinel Lymph Node Biopsy, Skin Neoplasms, Clinical Sciences, Oncology and Carcinogenesis
Abstract

ImportanceUse of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care.ObjectiveTo develop guidelines within the national Melanoma Prevention Working Group (MPWG) on integration of GEP testing into the management of patients with CM, including (1) review of published data using GEP tests, (2) definition of acceptable performance criteria, (3) current recommendations for use of GEP testing in clinical practice, and (4) considerations for future studies.Evidence reviewThe MPWG members and other international melanoma specialists participated in 2 online surveys and then convened a summit meeting. Published data and meeting abstracts from 2015 to 2019 were reviewed.FindingsThe MPWG members are optimistic about the future use of prognostic GEP testing to improve risk stratification and enhance clinical decision-making but acknowledge that current utility is limited by test performance in patients with stage I disease. Published studies of GEP testing have not evaluated results in the context of all relevant clinicopathologic factors or as predictors of regional nodal metastasis to replace sentinel lymph node biopsy (SLNB). The performance of GEP tests has generally been reported for small groups of patients representing particular tumor stages or in aggregate form, such that stage-specific performance cannot be ascertained, and without survival outcomes compared with data from the American Joint Committee on Cancer 8th edition melanoma staging system international database. There are significant challenges to performing clinical trials incorporating GEP testing with SLNB and adjuvant therapy. The MPWG members favor conducting retrospective studies that evaluate multiple GEP testing platforms on fully annotated archived samples before embarking on costly prospective studies and recommend avoiding routine use of GEP testing to direct patient management until prospective studies support their clinical utility.Conclusions and relevanceMore evidence is needed to support using GEP testing to inform recommendations regarding SLNB, intensity of follow-up or imaging surveillance, and postoperative adjuvant therapy. The MPWG recommends further research to assess the validity and clinical applicability of existing and emerging GEP tests. Decisions on performing GEP testing and patient management based on these results should only be made in the context of discussion of testing limitations with the patient or within a multidisciplinary group.

Published
2020

11. Erratum: Jeter JM, Bowles TL, Curiel‐Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18‐44.

Author

Jeter, Joanne M, Bowles, Tawnya L, Curiel-Lewandrowski, Clara, Swetter, Susan M, Filipp, Fabian V, Abdel-Malek, Zalfa A, Geskin, Larisa J, Brewer, Jerry D, Arbiser, Jack L, Gershenwald, Jeffrey E, Chu, Emily Y, Kirkwood, John M, Box, Neil F, Funchain, Pauline, Fisher, David E, Kendra, Kari L, Marghoob, Ashfaq A, Chen, Suephy C, Ming, Michael E, Albertini, Mark R, Vetto, John T, Margolin, Kim A, Pagoto, Sherry L, Hay, Jennifer L, Grossman, Douglas, Ellis, Darrel L, Kashani-Sabet, Mohammed, Mangold, Aaron R, Markovic, Svetomir N, Meyskens, Frank L Jr, Nelson, Kelly C, Powers, Jennifer G, Robinson, June K, Sahni, Debjani, Sekulic, Aleksandar, Sondak, Vernon K, Wei, Maria L, Zager, Jonathan S, Dellavalle, Robert P, Thompson, John A, Weinstock, Martin A, Leachman, Sancy A, and Cassidy, Pamela B

Subjects
Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Published
2019

12. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults

Author

Huang, Jennifer T, Coughlin, Carrie C, Hawryluk, Elena B, Hook, Kristen, Humphrey, Stephen R, Kruse, Lacey, Lawley, Leslie, Al-Sayegh, Hasan, London, Wendy B, Marghoob, Ashfaq, Phung, Thuy L, Pope, Elena, Gerami, Pedram, Schmidt, Birgitta, Robinson, Sarah, Bartenstein, Diana, Bahrani, Eman, Brahmbhatt, Meera, Chen, Lily, Haddock, Ellen, Mansour, Danny, Nguyen, Julie, Raisanen, Tom, Tran, Gary, Travis, Kate, Wolner, Zachary, and Eichenfield, Lawrence F

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prevention, Pediatric, Clinical Research, Adolescent, Antifungal Agents, Antineoplastic Agents, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Case-Control Studies, Child, Child, Preschool, Female, Genetic Predisposition to Disease, Humans, Immunosuppressive Agents, Infant, Male, Radiotherapy, Retrospective Studies, Risk Factors, Skin Neoplasms, United States, Voriconazole, Young Adult, basal cell nevus syndrome, chemotherapy, genodermatosis, iatrogenic, prolonged immunosuppression, radiation therapy, voriconazole, xeroderma pigmentosum, Human Movement and Sports Sciences, Paediatrics and Reproductive Medicine, Pediatrics, Paediatrics
Abstract

ObjectiveTo identify risk factors associated with nonmelanoma skin cancer (NMSC) occurrence and survival in children.Study designThis was a multicenter, retrospective, case-control study of patients 12 months prior to diagnosis and 49% of patients were diagnosed with ≥2 skin cancers. At last follow-up, 5% (6 of 124) of patients with NMSC died. Voriconazole exposure was noted in 7 cases and associated with worse 3-year overall survival (P = .001).ConclusionsNMSC in children and young adults is often associated with a predisposing condition or iatrogenic exposure. High-risk patients should be identified early to provide appropriate counseling and management.

Published
2019

14. Development of a core outcome set for basal cell carcinoma

Author

Schlessinger, Daniel I., Reynolds, Kelly A., Dirr, McKenzie A., Ibrahim, Sarah A., Yanes, Arianna F., Lazaroff, Jake M., Godinez-Puig, Victoria, Chen, Brian R., Kurta, Anastasia O., Cotseones, Jill K., Chiren, Sarah G., Furlan, Karina C., Iyengar, Sanjana, Behshad, Ramona, DeHoratius, Danielle M., Denes, Pablo, Drucker, Aaron M., Dzubow, Leonard M., Etzkorn, Jeremy R., Harwood, Catherine A., Kim, John Y.S., Lawrence, Naomi, Lee, Erica H., Lissner, Gary S., Marghoob, Ashfaq A., Matin, Rubeta N., Mattox, Adam R., Mittal, Bharat B., Thomas, J. Regan, Zhou, Xiaolong Alan, Zloty, David, Schmitt, Jochen, Kirkham, Jamie J., Armstrong, April W., Basset-Seguin, Nicole, Billingsley, Elizabeth M., Bordeaux, Jeremy S., Brewer, Jerry, Brown, Marc, Brown, Mariah, Collins, Scott A.B., Fargnoli, Maria Concetta, De Azevedo, Sergio Jobim, Dummer, Reinhard, Eggermont, Alexander, Goldman, Glenn D., Haedersdal, Merete, Hale, Elizabeth K., Hanlon, Allison, Harms, Kelly L., Huang, Conway C., Hurst, Eva A., In, Gino K., Kelleners-Smeets, Nicole, Kheterpal, Meenal, Leshin, Barry, Mcdonald, Michel, Miller, Stanley J., Miller, Alexander, Mostow, Eliot N., Trakatelli, Myrto, Nehal, Kishwer S., Ratner, Desiree, Rogers, Howard, Sarin, Kavita Y., Soon, Seaver L., Stasko, Thomas, Storrs, Paul A., Tagliaferri, Luca, Vidimos, Allison T., Wong, Sandra L., Yu, Siegrid S., Zalaudek, Iris, Zeitouni, Nathalie C., Zitelli, John A., Poon, Emily, Sobanko, Joseph F., Cartee, Todd V., Maher, Ian A., and Alam, Murad

Published
2022
Full Text
View/download PDF

16. Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society

Author

Pham, Félix, Boespflug, Amélie, Duru, Gérard, Phan, Alice, Poulalhon, Nicolas, Weiler, Laura, Tanaka, Masaru, Lallas, Aimilios, Ogata, Dai, Davaine, Anne Céline, Bahadoran, Philippe, Balguerie, Xavier, Kamińska-Winciorek, Grażyna, Tromme, Isabelle, Correia, Osvaldo, Kim, Moon-Bum, Marghoob, Ashfaq A., Linda Martin, Guitera, Pascale, Meziane, Mariame, Miquel, Juliette, Mun, Je-Ho, Argenziano, Giuseppe, Bessis, Didier, Bourke, Johnny, Mijuskovic, Zeljko, Chiaverini, Christine, Corven-Benoit, Cloé, Droitcourt, Catherine, Skowron, François, Marque, Myriam, Zalaudek, Iris, Rosendahl, Cliff, Moreno-Ramirez, David, Vabres, Pierre, Haenssle, Holger, Malvehy, Josep, Puig, Susana, Robert, Caroline, Schopf, Thomas R., Scope, Alon, Dalle, Stéphane, and Thomas, Luc

Published
2022
Full Text
View/download PDF

18. International Skin Imaging Collaboration‐Designated Diagnoses (ISIC‐DX): Consensus terminology for lesion diagnostic labeling.

Author

Scope, Alon, Liopyris, Konstantinos, Weber, Jochen, Barnhill, Raymond L., Braun, Ralph P., Curiel‐Lewandrowski, Clara N., Elder, David E., Ferrara, Gerardo, Grant‐Kels, Jane M., Jeunon, Thiago, Lallas, Aimilios, Lin, Jennifer Y., Marchetti, Michael A., Marghoob, Ashfaq A., Navarrete‐Dechent, Cristian, Pellacani, Giovanni, Soyer, Hans Peter, Stratigos, Alexander, Thomas, Luc, and Kittler, Harald

Subjects
SKIN imaging, SKIN tumors, ARTIFICIAL intelligence, SYNONYMS, LEXICON
Abstract

Background: A common terminology for diagnosis is critically important for clinical communication, education, research and artificial intelligence. Prevailing lexicons are limited in fully representing skin neoplasms. Objectives: To achieve expert consensus on diagnostic terms for skin neoplasms and their hierarchical mapping. Methods: Diagnostic terms were extracted from textbooks, publications and extant diagnostic codes. Terms were hierarchically mapped to super‐categories (e.g. 'benign') and cellular/tissue‐differentiation categories (e.g. 'melanocytic'), and appended with pertinent‐modifiers and synonyms. These terms were evaluated using a modified‐Delphi consensus approach. Experts from the International‐Skin‐Imaging‐Collaboration (ISIC) were surveyed on agreement with terms and their hierarchical mapping; they could suggest modifying, deleting or adding terms. Consensus threshold was >75% for the initial rounds and >50% for the final round. Results: Eighteen experts completed all Delphi rounds. Of 379 terms, 356 (94%) reached consensus in round one. Eleven of 226 (5%) benign‐category terms, 6/140 (4%) malignant‐category terms and 6/13 (46%) indeterminate‐category terms did not reach initial agreement. Following three rounds, final consensus consisted of 362 terms mapped to 3 super‐categories and 41 cellular/tissue‐differentiation categories. Conclusions: We have created, agreed upon, and made public a taxonomy for skin neoplasms and their hierarchical mapping. Further study will be needed to evaluate the utility and completeness of the lexicon. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

19. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials

Author

Jeter, Joanne M, Bowles, Tawnya L, Curiel-Lewandrowski, Clara, Swetter, Susan M, Filipp, Fabian V, Abdel-Malek, Zalfa A, Geskin, Larisa J, Brewer, Jerry D, Arbiser, Jack L, Gershenwald, Jeffrey E, Chu, Emily Y, Kirkwood, John M, Box, Neil F, Funchain, Pauline, Fisher, David E, Kendra, Kari L, Marghoob, Ashfaq A, Chen, Suephy C, Ming, Michael E, Albertini, Mark R, Vetto, John T, Margolin, Kim A, Pagoto, Sherry L, Hay, Jennifer L, Grossman, Douglas, Ellis, Darrel L, Kashani-Sabet, Mohammed, Mangold, Aaron R, Markovic, Svetomir N, Meyskens, Frank L, Nelson, Kelly C, Powers, Jennifer G, Robinson, June K, Sahni, Debjani, Sekulic, Aleksandar, Sondak, Vernon K, Wei, Maria L, Zager, Jonathan S, Dellavalle, Robert P, Thompson, John A, Weinstock, Martin A, Leachman, Sancy A, and Cassidy, Pamela B

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Prevention, Clinical Trials and Supportive Activities, Cancer, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, 3.3 Nutrition and chemoprevention, 6.9 Resources and infrastructure (treatment evaluation), Animals, Anticarcinogenic Agents, Chemoprevention, Clinical Trials, Phase III as Topic, Drug Development, Drug Repositioning, Female, Humans, Male, Melanoma, Radiation-Protective Agents, Skin Neoplasms, biomarkers, chemoprevention, human model systems, melanoma, natural products, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

Recent progress in the treatment of advanced melanoma has led to unprecedented improvements in overall survival and, as these new melanoma treatments have been developed and deployed in the clinic, much has been learned about the natural history of the disease. Now is the time to apply that knowledge toward the design and clinical evaluation of new chemoprevention agents. Melanoma chemoprevention has the potential to reduce dramatically both the morbidity and the high costs associated with treating patients who have metastatic disease. In this work, scientific and clinical melanoma experts from the national Melanoma Prevention Working Group, composed of National Cancer Trials Network investigators, discuss research aimed at discovering and developing (or repurposing) drugs and natural products for the prevention of melanoma and propose an updated pipeline for translating the most promising agents into the clinic. The mechanism of action, preclinical data, epidemiological evidence, and results from available clinical trials are discussed for each class of compounds. Selected keratinocyte carcinoma chemoprevention studies also are considered, and a rationale for their inclusion is presented. These data are summarized in a table that lists the type and level of evidence available for each class of agents. Also included in the discussion is an assessment of additional research necessary and the likelihood that a given compound may be a suitable candidate for a phase 3 clinical trial within the next 5 years.

Published
2019

20. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

Author

Sahu, Aditi, Kose, Kivanc, Kraehenbuehl, Lukas, Byers, Candice, Holland, Aliya, Tembo, Teguru, Santella, Anthony, Alfonso, Anabel, Li, Madison, Cordova, Miguel, Gill, Melissa, Fox, Christi, Gonzalez, Salvador, Kumar, Piyush, Wang, Amber Weiching, Kurtansky, Nicholas, Chandrani, Pratik, Yin, Shen, Mehta, Paras, Navarrete-Dechent, Cristian, Peterson, Gary, King, Kimeil, Dusza, Stephen, Yang, Ning, Liu, Shuaitong, Phillips, William, Guitera, Pascale, Rossi, Anthony, Halpern, Allan, Deng, Liang, Pulitzer, Melissa, Marghoob, Ashfaq, Chen, Chih-Shan Jason, Merghoub, Taha, and Rajadhyaksha, Milind

Published
2022
Full Text
View/download PDF

21. Special Locations

Author

Hocker, Sarah N., primary, Rabinovitz, Harold S., additional, Oliviero, Margaret C., additional, and Marghoob, Ashfaq A., additional

Published
2022
Full Text
View/download PDF

23. Nonmelanocytic Lesions

Author

Hocker, Sarah N., primary, Rabinovitz, Harold S., additional, Oliviero, Margaret C., additional, and Marghoob, Ashfaq A., additional

Published
2022
Full Text
View/download PDF

25. Melanocytic Lesions

Author

Navarrete-Dechent, Cristian, primary, Liopyris, Konstantinos, additional, Jaimes, Natalia, additional, and Marghoob, Ashfaq A., additional

Published
2022
Full Text
View/download PDF

30. Introduction

Author

Marghoob, Ashfaq A, primary, Braun, Ralph P, additional, and Jaimes, Natalia, additional

Published
2022
Full Text
View/download PDF

37. Acquired Precursor Lesions and Phenotypic Markers of Increased Risk for Cutaneous Melanoma

Author

Navarrete-Dechent, Cristian, Scope, Alon, Tsao, Hensin, Marghoob, Nadeem G., Sober, Arthur J., Marghoob, Ashfaq A., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

38. Clinical Presentations of Melanoma

Author

Halpern, Allan C., Marghoob, Ashfaq A., Sober, Arthur J., Mar, Victoria, Marchetti, Michael A., Balch, Charles M., editor, Atkins, Michael B., editor, Garbe, Claus, editor, Gershenwald, Jeffrey E., editor, Halpern, Allan C., editor, Kirkwood, John M., editor, McArthur, Grant A., editor, Thompson, John F., editor, and Sober, Arthur J., editor

Published
2020
Full Text
View/download PDF

40. Flat Pigmented Lesions on the Face

Author

Dufrechou Varela, Lídice, Marchiori Bakos, Renato, Navarrete-Dechent, Cristian, Uribe, Pablo, Marghoob, Ashfaq A., Arceu, Montserrat, Lallas, Aimilios, Cabo, Horacio, editor, and Lallas, Aimilios, editor

Published
2020
Full Text
View/download PDF

42. Clinical Utility of a Digital Dermoscopy Image-Based Artificial Intelligence Device in the Diagnosis and Management of Skin Cancer by Dermatologists.

Author

Witkowski, Alexander M., Burshtein, Joshua, Christopher, Michael, Cockerell, Clay, Correa, Lilia, Cotter, David, Ellis, Darrell L., Farberg, Aaron S., Grant-Kels, Jane M., Greiling, Teri M., Grichnik, James M., Leachman, Sancy A., Linfante, Anthony, Marghoob, Ashfaq, Marks, Etan, Nguyen, Khoa, Ortega-Loayza, Alex G., Paragh, Gyorgy, Pellacani, Giovanni, and Rabinovitz, Harold

Subjects
SKIN tumors, COMPUTER-assisted image analysis (Medicine), MELANOMA, SKIN diseases, ARTIFICIAL intelligence, NEVUS, CANCER patients, CERTIFICATION, DESCRIPTIVE statistics, DERMOSCOPY, DERMATOLOGISTS, MACHINE learning, COMPARATIVE studies, ALGORITHMS, MEDICAL triage
Abstract

Simple Summary: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. We evaluated the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm (DDI-AI device) on the diagnosis and management of skin cancers. Thirty-six United States board-certified dermatologists evaluated 50 cases with clinical images and DDI of the same skin lesions (25 malignant and 25 benign), first without and then with knowledge of the DDI-AI device output. We identified that when using the DDI-AI device, management sensitivity, management specificity, diagnostic sensitivity, and diagnostic specificity all increased over baseline use of clinical images and dermoscopy images. Hence, the use of the DDI-AI device may quickly, safely, and effectively improve dermoscopy performance, skin cancer diagnosis, and management when used by dermatologists, independent of training and experience. Background: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. Objective: To evaluate the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm (DDI-AI device) on the diagnosis and management of skin cancers by dermatologists. Methods: Thirty-six United States board-certified dermatologists evaluated 50 clinical images and 50 digital dermoscopy images of the same skin lesions (25 malignant and 25 benign), first without and then with knowledge of the DDI-AI device output. Participants indicated whether they thought the lesion was likely benign (unremarkable) or malignant (suspicious). Results: The management sensitivity of dermatologists using the DDI-AI device was 91.1%, compared to 84.3% with DDI, and 70.0% with clinical images. The management specificity was 71.0%, compared to 68.4% and 64.9%, respectively. The diagnostic sensitivity of dermatologists using the DDI-AI device was 86.1%, compared to 78.8% with DDI, and 63.4% with clinical images. Diagnostic specificity using the DDI-AI device increased to 80.7%, compared to 75.9% and 73.6%, respectively. Conclusion: The use of the DDI-AI device may quickly, safely, and effectively improve dermoscopy performance, skin cancer diagnosis, and management when used by dermatologists, independent of training and experience. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. The Impact of Melanoma Imaging Biomarker Cues on Detection Sensitivity and Specificity in Melanoma versus Clinically Atypical Nevi.

Author

Agüero, Rosario, Buchanan, Kendall L., Navarrete-Dechent, Cristián, Marghoob, Ashfaq A., Stein, Jennifer A., Landy, Michael S., Leachman, Sancy A., Linden, Kenneth G., Garcet, Sandra, Krueger, James G., and Gareau, Daniel S.

Subjects
MELANOMA diagnosis, SCHOOL environment, SKIN tumors, PROMPTS (Psychology), RESEARCH funding, NEVUS, ARTIFICIAL intelligence, EARLY detection of cancer, TUMOR markers, DESCRIPTIVE statistics, DECISION making, DERMOSCOPY, DERMATOLOGISTS, PHYSICIANS, SENSITIVITY & specificity (Statistics), ALGORITHMS
Abstract

Simple Summary: Early detection of melanoma and differentiation from benign nevi can be challenging even for the most experienced dermatologists. To improve melanoma detection, artificial intelligence algorithms incorporating dermoscopy have been developed, but lack transparency and therefore have limited training value for healthcare providers. To address this, an automated approach utilizing imaging biomarker cues (IBCs), logical features extracted from images that mimic expert dermatologists' dermoscopic pattern recognition skills, was developed. This study excluded deep learning approaches to which IBCs are complementary or alternative. Ten participants assessed 78 dermoscopic images (39 melanomas and 39 nevi) first without IBCs and then with IBCs. Using IBCs significantly improved diagnostic accuracy: sensitivity increased significantly from 73.69% to 81.57% (p = 0.0051) and specificity increased from 60.50% to 67.25% (p = 0.059). These results indicate that incorporating IBCs can significantly enhance melanoma diagnosis, with potential implications for improved screening practices. Further research is needed to confirm these findings across a variety of healthcare providers. Incorporation of dermoscopy and artificial intelligence (AI) is improving healthcare professionals' ability to diagnose melanoma earlier, but these algorithms often suffer from a "black box" issue, where decision-making processes are not transparent, limiting their utility for training healthcare providers. To address this, an automated approach for generating melanoma imaging biomarker cues (IBCs), which mimics the screening cues used by expert dermoscopists, was developed. This study created a one-minute learning environment where dermatologists adopted a sensory cue integration algorithm to combine a single IBC with a risk score built on many IBCs, then immediately tested their performance in differentiating melanoma from benign nevi. Ten participants evaluated 78 dermoscopic images, comprised of 39 melanomas and 39 nevi, first without IBCs and then with IBCs. Participants classified each image as melanoma or nevus in both experimental conditions, enabling direct comparative analysis through paired data. With IBCs, average sensitivity improved significantly from 73.69% to 81.57% (p = 0.0051), and the average specificity improved from 60.50% to 67.25% (p = 0.059) for the diagnosis of melanoma. The index of discriminability (d′) increased significantly by 0.47 (p = 0.002). Therefore, the incorporation of IBCs can significantly improve physicians' sensitivity in melanoma diagnosis. While more research is needed to validate this approach across other healthcare providers, its use may positively impact melanoma screening practices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. A retrospective multicenter study of fatal pediatric melanoma

Author

Hawryluk, Elena B., Moustafa, Danna, Bartenstein, Diana, Brahmbhatt, Meera, Cordoro, Kelly, Gardner, Laura, Gauthier, Abigail, Grossman, Douglas, Gupta, Deepti, Hunt, Raegan D., Jen, Melinda, Kao, Pei-Chi, Kruse, Lacey L., Lawley, Leslie P., London, Wendy B., Mansour, Danny, O'Haver, Judith A., Phung, Thuy, Pope, Elena, Price, Harper N., Rogers, Tova, Shah, Sonal D., Wolner, Zachary, Huang, Jennifer, and Marghoob, Ashfaq A.

Published
2020
Full Text
View/download PDF

46. Improvement of diagnostic confidence and management of equivocal skin lesions by integration of reflectance confocal microscopy in daily practice: Prospective study in 2 referral skin cancer centers

Author

Yélamos, Oriol, Manubens, Elena, Jain, Manu, Chavez-Bourgeois, Marion, Pulijal, Sri V., Dusza, Stephen W., Marchetti, Michael A., Barreiro, Alicia, Marino, Maria L., Malvehy, Josep, Cordova, Miguel A., Rossi, Anthony M., Rajadhyaksha, Milind, Halpern, Allan C., Puig, Susana, Marghoob, Ashfaq A., and Carrera, Cristina

Published
2020
Full Text
View/download PDF

48. International Skin Imaging Collaboration‐Designated Diagnoses (ISIC‐DX): Consensus terminology for lesion diagnostic labeling

Author

Scope, Alon, primary, Liopyris, Konstantinos, additional, Weber, Jochen, additional, Barnhill, Raymond L., additional, Braun, Ralph P., additional, Curiel‐Lewandrowski, Clara N., additional, Elder, David E., additional, Ferrara, Gerardo, additional, Grant‐Kels, Jane M., additional, Jeunon, Thiago, additional, Lallas, Aimilios, additional, Lin, Jennifer Y., additional, Marchetti, Michael A., additional, Marghoob, Ashfaq A., additional, Navarrete‐Dechent, Cristian, additional, Pellacani, Giovanni, additional, Soyer, Hans Peter, additional, Stratigos, Alexander, additional, Thomas, Luc, additional, Kittler, Harald, additional, Rotemberg, Veronica, additional, and Halpern, Allan C., additional

Published
2024
Full Text
View/download PDF

50. The role of ultraviolet-induced fluorescence dermatoscopy for the detection of multiple aggregated yellow-white globules in basal cell carcinoma.

Author

Navarrete-Dechent, Cristian, Pietkiewicz, Pawel, Astronave, Gisel, Marghoob, Nadeem G., Dusza, Stephen W., Lorenzoni, Josefina, Boleira, Manuela, Cristopher, Michael, Aguero, Rosario, Bustos, Sergio, Jaimes, Natalia, Kurpis, Maria, Hidalgo, Leonel, Abarzua-Araya, Alvaro, Zoroquiain, Pablo, Uribe, Pablo, Cárdenas, Consuelo, Droppelmann, Katherine, and Marghoob, Ashfaq A.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results